Latest Conference Coverage

Blarcamesine Shows Significant Slowing of Alzheimer Disease in Phase 2/3 Trial

Anavex Life Sciences intends to submit a full regulatory application for blarcamesine as a potential treatment for AD in Europe by Q4 2024.

Future Directions on Understanding the Link Between Wildfire Particulates and Dementia: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPH

A duo of experts highlighted the need for further studies on the exploration of how exposure to wildfire particulate matter impacts neurodegenerative diseases. [WATCH TIME: 2 minutes]

Impact of Blood Tests on Wait Times and Treatment in Alzheimer Disease: Soeren Mattke, MD, DSc

The director of the Brain Health Observatory at the University of Southern California discussed how blood tests for Alzheimer disease could significantly reduce diagnostic wait times and improve treatment monitoring. [WATCH TIME: 4 minutes]

NeuroVoices: Stina Saunders, PhD, on the Utility of the Electronic Person-Specific Outcome Measure on Brain Health

The personalized medicine lead at Linus Health provided clarity on a new outcome measure that captures various perspectives about what matters to individuals and their brain health.

The Need for Flexibility and Patient-Centered Approaches in Clinical Trials for Cervical Dystonia: Anna Castagna, MD

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS stressed how new clinical trial designs for cervical dystonia should incorporate more flexible and patient-centered approaches, including new measurement scales and the use of technology. [WATCH TIME: 5 minutes]

Mechanism of Action and Potential of Anti-Tau Agent BIIB080: Ivana Rubino, PhD, BSc

The head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen provided perspective on the promising development of BIIB080, a treatment thought to work by reducing forms of tau protein. [WATCH TIME: 4 minutes]

Gaining Greater Insights on the Role of Genetics and Microglia and Alzheimer Disease: Gareth Howell, PhD

The professor of neurology and Diana Davis Spencer Foundation Chair at the Jackson Laboratory provided context on a presentation from AAIC 2024 highlighting the ways genetics can impact microglia function and its relation to Alzheimer disease. [WATCH TIME: 3 minutes]

Assessing the Felix NeuralAI Wristband for Essential Tremor Management: Zhen Zhang, PhD, & Rajesh Pahwa, MD

The president at Fasikl and the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center talked about results from a pilot study assessing the Felix Neural AI wristband in patients with essential tremor. [WATCH TIME: 4 minutes]

Plasma p-tau217 Effectively Pre-Screens for Amyloid-β Positivity in Alzheimer Disease

Using plasma p-tau217 shows promise as an effective, less invasive pre-screening method for identifying amyloid-β positive individuals in Alzheimer disease clinical trials.

ALPHA-1062 Approved for Alzheimer Disease, GLP-1 Agonist Shows Neuroprotective Effects Against Dementia, Lecanemab 3-Year Data Reported

Neurology News Network. for the week ending August 3, 2024. [WATCH TIME: 4 minutes]

Supportive Evidence for CT1812 as Treatment for Alzheimer Disease: Anthony Caggiano, MD, PhD

The chief medical officer and head of Research & Development at Cognition Therapeutics provided clinical insight on new phase 2 data and the mechanism of action of CT1812, a therapy in development for Alzheimer disease. [WATCH TIME: 5 minutes]

Evaluating the Duration and Efficacy of Botulinum Toxin Treatment in Cervical Dystonia: Anna Castagna, MD

The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS talked about a recent study that examined the varying methods and results of clinical trials assessing the duration and efficacy of botulinum toxin treatment in cervical dystonia. [WATCH TIME: 7 minutes]

Open Label Extension Data Shows Lecanemab’s Continued Effect on Alzheimer Disease After 3 Years

The 3-year data highlighted the safety profile of lecanemab and its disease-modifying effects on tau accumulation and other biomarkers related to AD pathology.

Highly Accurate Blood Test Enhances Alzheimer Diagnosis in Primary and Secondary Care

The use of a blood test significantly improved diagnostic accuracy compared with standard clinical evaluations for Alzheimer disease, especially in primary and secondary care settings.

Recent Advancements in Alzheimer Disease Research Presented at AAIC 2024: Rebecca M. Edelmayer, PhD

The vice president of scientific engagement at Alzheimer's Association talked about recent studies that highlight the progress made in blood biomarker tests for diagnosis, the impact of air pollution on brain health, and promising treatments for Alzheimer disease. [WATCH TIME: 8 minutes]

GLP-1 Agonist Liraglutide Shows Protective Effects on Alzheimer Disease in Phase 2 Trial

Although the primary endpoint of cerebral glucose metabolic rate change was not met, secondary endpoints showed significant benefits in brain volume and cognitive measures, further supporting the potential of GLP-1 agonists in AD.

AAIC Data Highlights Therapeutic Potential of CT1812 in Alzheimer Disease

CT1812, a sigma-2 receptor ligand, showed favorable changes in biomarkers like Aß40, Aß42, and neurofilament light (NfL), indicating its potential as a synaptoprotective agent.

Higher MIND Diet Scores Associated With Larger Brain MRI Hippocampal Volume

Higher MIND diet scores correlate with larger hippocampal volume in older adults, suggesting potential benefits for brain health.

Processed Red Meat Intake Linked to Increased Dementia Risk and Cognitive Decline

A study recently presented at AAIC 2024 showed that higher consumption of processed red meat significantly increased the risk of dementia and cognitive decline among adults in the United States.

NeuroVoices: Soeren Mattke, MD, DSc, on Utilizing Blood Tests to Reduce Wait Times and Improve Diagnosis in Alzheimer Disease

The director of the Brain Health Observatory at the University of Southern California discussed the potential impact of Alzheimer disease blood tests on reducing clinic wait times and improving the diagnostic process in primary care.

CoMPoSER, Developing a Music-Based Sleep App for Patients With Dementia and Caregivers: Darina Petrovsky, PhD, RN

The assistant professor at Duke University School of Nursing talked about a project aimed at developing a music-based mobile app to improve sleep for individuals with dementia and their caregivers. [WATCH TIME: 5 minutes]

Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD

The co-founder and chief science officer at Longeveron provided commentary on the therapeutic potential of Lomecel-B, a living cell product in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]

Y-Secretase Modulator RG6289 Produces Dose-Dependent Shift of Amyloid-ß Monomers in Phase 1 Study

A small clinical trial showed RG6289 dose-dependently altered amyloid-ß monomers in CSF, supporting its development for Alzheimer's disease.

Potential Cognitive Benefits of Using GLP-1 Analogs for Alzheimer Disease Treatment: Paul Edison, MD, PhD

The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

Education and Number of Household Members Negatively Impacts Cognitive Outcomes in Latino Individuals

In Latino individuals, larger household size negatively affects MoCA scores, while higher education positively impacts cognitive outcomes, per SERVE OC trial data.

Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN

The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]

Innovative Phase 2 Proof-of-Concept Trial to Test Effects of Benfotiamine as Alzheimer Treatment

The trial will use phase 2a to determine the optimal dosage while phase 2b will assess efficacy and long-term safety of the optimized dose against a placebo arm.

Alzheimer Agent T3D-959 Demonstrates Disease-Modifying Effects in Phase 2 PIONEER Trial

The drug showed a strong safety profile and met primary endpoints, showing efficacy in slowing clinical and biological decline and supporting further investigation in a phase 2/3 trial.

Exploring Wildfire Smoke Exposure and Risk of Dementia in an Older Patient Population: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPH

A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]

Alzheimer Vaccine ALZ-101 Shows Safety, Oligomer-Specific Humoral Immune Response in Early-Stage Trial

The vaccine induced a specific humoral immune response, positively affecting several AD-related biomarkers, and showed potential as a treatment for AD, with further trials planned.